CHICAGO — Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting.More than half of patients who received zanidatamb (Jazz Pharmaceuticals/Zymeworks) monotherapy survived at least a year and median OS exceeded 15 months.
/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings,.
Zanidatamab induces response in refractory HER2-positive biliary tract cancer healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.